Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 na?ve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at lea

Advanced Solid Tumors

Sub-indication: Cohort 1 - Gastroesophageal adenocarcinoma; Cohort 2 - Any type of solid tumor cancer that benefitted previously from an anti-PD-1/PD-(L)1 treatment; Cohort 3 - : Did not benefit from a previous anti-PD-1/PD-(L)1 treatment

Line of Therapy: 2nd line advanced and/or metastatic solid tumors

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Boehringer Ingelheim

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.